Panbela Therapeutics
- Company typePublic
- Founded2011
- HeadquartersMinnesota City, United States
- Headcount1–10
- GTM typeB2B
- OfferingHardware or Manufacturing
Panbela Therapeutics firmographics
Firmographics- Name
- Panbela Therapeutics
- Legal name
- Panbela Therapeutics, Inc.
- Website
- https://panbela.com
- Company type
- Public
- Founded year
- 2011
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Ownership category
- akta.pro rank
Panbela Therapeutics industry classification
Industry- Product category
- Clinical-Stage Oncology Biopharmaceuticals
- NAICS
- Pharmaceutical and Medicine Manufacturing (3254)
- SIC
- Pharmaceutical Preparations (2834)
- akta.pro primary industry
- Gastroenterology Specialty Pharmaceuticals (HLAIACAE)
Keywords
Where Panbela Therapeutics is headquartered
LocationHeadquarters
- HQ city
- Minnesota City
- HQ country
- United States
- HQ region
- North America
Markets served
Panbela Therapeutics business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations, Marketing or Sales, Others
Revenue model
- Product Revenue: Pre-commercial stage; no current revenue from product sales as therapeutics are in clinical development phase
Go-to-market motion1 record
Marketing channels1 record
Panbela Therapeutics product offering
Product offeringCore offering
Panbela Therapeutics is a clinical-stage biopharmaceutical company developing small molecule pharmaceutical candidates for oncology indications, with a primary focus on pancreatic ductal adenocarcinoma and other solid tumors. The company's pipeline includes Ivospemin (SBP-101) and Flynpovi, which are undergoing clinical trials. The company is pre-commercial and has no approved or revenue-generating products.
Product overview
Panbela Therapeutics is a clinical-stage biopharmaceutical company developing cancer therapeutics. The company's product portfolio includes Ivospemin (SBP-101) and Flynpovi, both in active clinical development for various cancer indications. The company has pursued strategic transactions including the acquisition of Cancer Prevention Pharmaceuticals Inc. in 2022 to expand its pipeline, and divested its pediatric neuroblastoma program (eflornithine) to US WorldMeds in 2023.
Differentiator
Problem solved
Functional benefit
Products and services
- Ivospemin (SBP-101) Ivospemin (SBP-101) is a clinical-stage small molecule therapeutic compound being developed by Panbela Therapeutics for the treatment of various cancers, including oncology indications in the company's pipeline with ongoing clinical trials.
- Flynpovi Flynpovi is a clinical-stage therapeutic compound being developed by Panbela Therapeutics for cancer treatment as part of the company's ongoing clinical development efforts in its oncology portfolio.
Companies that use Panbela Therapeutics
Customer profileSegments1 record
Ideal customer profiles2 records
Panbela Therapeutics technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature2 records
Panbela Therapeutics partnerships and signals
Strategic signalPartnerships
Two partnerships are on record, tiered minor and core.
- US WorldMedsminorPanbela divested assets related to its pediatric neuroblastoma program to US WorldMeds, a Kentucky-based pharmaceutical company, for up to $9.5 million. The deal involves milestone payments based on clinical development, regulatory approval, and sales of eflornithine, a drug developed for neuroblastoma.
- Cancer Prevention Pharmaceuticals, Inc.corePanbela Therapeutics announced acquisition of Cancer Prevention Pharmaceuticals, Inc., expected to close by Q2 2022. The merger aims to expand the company's pipeline and develop therapeutics for various cancers, including a fully funded registration trial.
Scale indicators9 records
Recent moves6 records
Expansion highlights4 records
Panbela Therapeutics competitors and assessment
Company assessmentDirect peers
- Cardiff Oncology: Clinical-stage small-molecule oncology company developing therapeutics for solid tumors including GI malignancies. Comparable size, public-listing profile, and dependence on incremental financing to advance a pre-commercial pipeline.
- Rafael Holdings: Clinical-stage, small-cap oncology company also developing therapeutics for difficult-to-treat cancers including pancreatic cancer. Comparable in being a publicly traded, sub-scale biotech where pipeline assets and licensing deals drive valuation, with similar funding-raises/dilution dynamics.
- Moleculin Biotech: Clinical-stage small-molecule oncology biotech developing candidates for hard-to-treat solid tumors, including pancreatic and GI cancers. Comparable in scale, public listing, and reliance on clinical readouts and equity raises to advance pipeline.
- Tyme Technologies: Pre-revenue clinical-stage oncology biotech whose lead program was a small-molecule therapy for metastatic pancreatic cancer. Comparable as a micro-cap public company developing novel small-molecule oncology drugs in highly underserved indications.
Broad incumbents
- Puma Biotechnology: Public specialty oncology company commercializing and developing small-molecule cancer therapies. While larger and commercial-stage, it provides a comparable business model of small-molecule oncology asset development, registration trials, and public-market financing.
- RedHill Biopharma: Specialty pharmaceutical company developing and commercializing small-molecule therapeutics, including in gastrointestinal and pancreatic-related indications. Comparable in small-molecule specialty pharma orientation, though RedHill is more advanced commercially.
- AVEO Pharmaceuticals: Oncology-focused company with small-molecule therapeutics targeting cancers including GI malignancies. Comparable in clinical-stage small-molecule oncology development with public-listing and financing dynamics similar to Panbela's.
Emerging players
- Cogent Biosciences: Public clinical-stage precision oncology company developing small-molecule therapies with a focus on gastrointestinal tumor subtypes and rare oncology indications. Comparable in clinical-stage profile and small-cap public-market financing strategy.
- Phio Pharmaceuticals: Public clinical-stage biotechnology company developing therapeutics for cancer, including solid tumor indications. Comparable as a micro-cap, clinical-stage biotech sustaining R&D through equity issuances while pursuing oncology pipeline readouts.
- Iterion Therapeutics: Clinical-stage developer of small-molecule oncology therapies with active programs in pancreatic and other solid tumors. Directly comparable in modality (small-molecule drug development), indication (pancreatic cancer), and pre-commercial profile.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat3 records
Key risks5 records
Key highlights4 records
Customer concentration
Panbela Therapeutics social profiles
Digital presencePanbela Therapeutics financial estimates
Financial estimateRevenue estimate
Valuation estimate
Panbela Therapeutics leadership team
Management profileNumber of profiles
Profiles6 records
Panbela Therapeutics subsidiaries and ownership
Company hierarchySubsidiaries1 record
Panbela Therapeutics funding detail
Funding detailFunding overview
Funding rounds15 records
Investors1 record
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Panbela Therapeutics M&A and investment
M&A and investmentM&A2 records
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Panbela Therapeutics
What does Panbela Therapeutics do?
Panbela Therapeutics is a clinical-stage biopharmaceutical company developing small molecule pharmaceutical candidates for oncology indications, with a primary focus on pancreatic ductal adenocarcinoma and other solid tumors. The company's pipeline includes Ivospemin (SBP-101) and Flynpovi, which are undergoing clinical trials. The company is pre-commercial and has no approved or revenue-generating products.
Is Panbela Therapeutics a public or private company?
Panbela Therapeutics is a public company. It is classified as public and is currently operating.
When was Panbela Therapeutics founded?
Panbela Therapeutics was founded in 2011. It employs 1 to 10 people.
Where is Panbela Therapeutics based?
Panbela Therapeutics is headquartered in Minnesota City, United States, in the North America region.
How does Panbela Therapeutics make money?
One revenue line is on record: product Revenue.
Who are Panbela Therapeutics's main competitors?
Direct peers on record are Cardiff Oncology, Rafael Holdings, Moleculin Biotech and Tyme Technologies. Broad incumbents are Puma Biotechnology, RedHill Biopharma and AVEO Pharmaceuticals. Emerging players are Cogent Biosciences, Phio Pharmaceuticals and Iterion Therapeutics.
Does Panbela Therapeutics have an API?
No public API is recorded for Panbela Therapeutics.
What industry is Panbela Therapeutics in?
Panbela Therapeutics's product category is Clinical-Stage Oncology Biopharmaceuticals. Its primary akta.pro industry code is HLAIACAE, Gastroenterology Specialty Pharmaceuticals. Its NAICS code is 3254 and its SIC code is 2834.